AR and prostate cancer: Interestingly, three major subgroups of genomic subcomplexes of AR interaction partners were identified, where FOXA1 and HOXB13, known transcription factors interacting with AR and affecting the AR cistrome in prostate cancer, dictate selective gain of function for AR action [104].